Connect with us

Marknadsnyheter

Abstracts för tre pipelineprodukter utvalda för 2018 ASCO Clinical Meeting

Published

on

on, maj 16, 2018 23:00 CET

Fas 1-studie av PARP-hämmaren 2X-121 utvald för muntlig presentation den 1 juni 2018

Hörsholm, Danmark och Cambridge, Massachusetts – 16 maj 2018 – Oncology Venture Sweden AB (”Oncology Venture”) meddelar idag att tre abstracts innehållande information om kliniska studier med bolagets läkemedelskandidater har accepterats av American Society for Clinical Oncology (ASCO) för 2018 ASCO Clinical Meeting. Noterbart är att Ruth Plummer, MD, PhD, FRCP, kommer att presentera ett abstract med information om den första fas 1-studien i människa med 2X-121, en undersökande PARP 1/2- samt tankyras 1/2-hämmare, som monoterapi i patienter med långt framskridna solida tumörer.

Titel på Abstract: First-in-human phase 1 study of the PARP/tankyrase inhibitor 2X-121 (E7449) as monotherapy in patients with advanced solid tumors and validation of a novel drug response predictor (DRP®) mRNA biomarker.
Abstractnummer: 224139
Datum: 1 juni 2018
Tid: 4:09 PM (CDT)

Utöver att utvärdera säkerhet, högsta tolererade dos samt antitumörverkningsgrad av 2X-121 bedömde studien även förmågan hos en ny tumör-agnostisk molekylärbiomarkör för att identifiera respondenter och icke-respondenter av 2X-121. Denna companion diagnostic, kallad 2X-121 DRP®, baseras på uttryck från 414 gener som är prediktiva för respons med 2X-121.

Efter avslutad studie applicerades 2X-121 DRP® på ett blindat sätt efter en förutbestämd analysplan. 2X-121 DRP förutspådde framgångsrikt respondenterna för behandling med 2X-121, oberoende av BRCA-mutationsstatus.

Oncology Venture inlicensierade detta anticancerläkemedel (tidigare känt som E7449) från Eisai Inc. i juli 2017. Oncology Venture kommer att inleda en klinisk fas 2-studie för att undersöka antitumörverkan och toleransen för 2X-121 hos av 2X-121 DRP® utvalda patienter med metastatisk bröstcancer.

Dr Plummer är chef för Sir Bobby Robson Cancer trials Research Centre vid Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, UK och var huvudprövare i den kliniska
Page 2 of 3

studien. Hon är medlem i Cancer Research UK (CRUK) Science Funding Committee och ordförande för CRUK New Agents Committee.

Två ytterligare abstract på Oncology Ventures pipeline accepterades av ASCO som elektroniska abstract enligt följande:

LiPlaCis
Titel på Abstract: Liposomal cisplatin response prediction in heavily pretreated breast cancer patients: A multigene biomarker in a prospective phase 2 study.
Abstractnummer: e13077

LiPlaCis är en lipidformulering av cisplatin, vilket är ett av de mest använda läkemedlen vid behandling av cancer. Denna förbättrade formulering möjliggör en mer selektiv upptagning av cisplatin vid tumörstället. När läkemedlet har samlats i cancervävnaden bryts LiPlaCis ned genom sekretorisk fosfolipas A2 (sPLA2), ett enzym som finns i tumörer. LiPlaCis:s lipidsammansättning är skräddarsydd för att vara specifikt känslig för nedbrytning av sPLA2-enzymet och därigenom för frisättning av det inkapslade cisplatinet.

APO010
Titel på Abstract: Characterization of resistance to APO010, a recombinant hexameric FAS ligand, in human myeloma cell lines.
Abstractnummer: e20025

APO010 är ett rekombinant, lösligt hexameriskt fusionsprotein bestående av tre human-Fas-ligand (FasL) extracellulära domäner kondenserade till den dimerbildande kollagedomänen av humant adiponektin med potentiella pro-apoptotiska och antineoplastiska aktiviteter. Sammansatt i en löslig hexamerisk struktur som efterliknar ligandklypningen av endogen aktiv FasL aktiverar APO010 Fasreceptorn, vilket resulterar i caspasberoende apoptos i mottagliga tumörcellpopulationer. FasL är ett transmembranprotein hos tumörnekrosfaktorn (TNF) superfamiljen och en pro-apoptotisk ligand för död-receptor-Fas.

För ytterligare information, vänligen kontakta

Ulla Hald Buhl, operativ chef, ansvarig för IR kommunikation Telefon: +45 2170 1049 E-mail: uhb@oncologyventure.com
Eller

Peter Buhl Jensen, VD Telefon: +45 21 60 89 22 E-mail: pbj@oncologyventure.com

Om Oncology Venture Sweden AB Oncology Venture Sweden AB arbetar med forskning och utveckling inom cancerläkemedel via det helägda danska företaget Oncology Venture ApS. Oncology Venture innehar licens att använda Drug Response Prediction – DRP® – för att signifikant kunna öka sannolikheten att lyckas i kliniska tester. DRP® har visat förmåga att ge statistiskt tillförlitliga förutsägelser för kliniska resultat av läkemedelsbehandling av cancerpatienter i 29 av 37 undersökta kliniska studier. Företaget använder sig av en modell som förbättrar oddsen jämfört med traditionell farmaceutisk utveckling. Istället för att behandla alla patienter som har en viss typ av cancer genscreenas först biopsier från patienternas tumörer, och endast de patienter som sannolikt kommer svara positivt på behandling med aktuell läkemedelskandidat inkluderas sedan i studien. Med en mer väldefinierad patientgrupp kan risker och kostnader minimeras, och utvecklingen effektiviseras.

Nuvarande produktportfölj: LiPlaCis® för bröstcancer i samarbete med Cadila Pharmaceuticals, Irofulven, utvecklad ur en svamp, mot prostatacancer, och APO010: en immunonkologisk produkt mot multipelt myelom (benmärgscancer).

Oncology Venture har bildat två spin-off-företag i form av specialbolag: 2X Oncology Inc. är ett USA-baserat företag som fokuserar på precisionsmedicin för kvinnliga cancerformer, för tillfället med en produktportfölj bestående av tre lovande produktkandidater i fas 2. OV-SPV 2 är ett danskt företag som ska testa och potentiellt utveckla en småmolekyl-kinashämmare från Novartis. Oncology Venture äger för närvarande 92 procent av 2X Oncology Inc. och 40 procent av OV-SPV2.

Continue Reading

Marknadsnyheter

Årsredovisning 2023 Thinc Collective AB (publ)

Published

on

By

Report this content

Idag tisdagen den 23/4 2024 publicerar Thinc Collective AB (publ) årsredovisningen för 2023.

Årsredovisningen finns tillgänglig på bolagets hemsida www.thinccollective.se

Continue Reading

Marknadsnyheter

Årsredovisning 2023 Thinc Collective AB (publ)

Published

on

By

Report this content

Idag tisdagen den 23/4 2024 publicerar Thinc Collective AB (publ) årsredovisningen för 2023.

Årsredovisningen finns tillgänglig på bolagets hemsida www.thinccollective.se

Continue Reading

Marknadsnyheter

UPS RELEASES 1Q 2024 EARNINGS

Published

on

By

  • Consolidated Revenues of $21.7B, Compared to $22.9B Last Year
  • Consolidated Operating Margin of 7.4%; Adjusted* Consolidated Operating Margin of 8.0%
  • Diluted EPS of $1.30; Adj. Diluted EPS of $1.43, Compared to $2.20 Last Year
  • Reaffirms Full-Year 2024 Financial Guidance

ATLANTA – April 23, 2024 – UPS (NYSE:UPS) today announced first-quarter 2024 consolidated revenues of $21.7 billion, a 5.3% decrease from the first quarter of 2023. Consolidated operating profit was $1.6 billion, down 36.5% compared to the first quarter of 2023, and down 31.5% on an adjusted basis. Diluted earnings per share were $1.30 for the quarter; adjusted diluted earnings per share of $1.43 were 35.0% below the same period in 2023. 

For the first quarter of 2024, GAAP results include a total charge of $110 million, or $0.13 per diluted share, comprised of after-tax transformation and other charges of $75 million and a non-cash, after-tax impairment charge of $35 million, driven by plans to consolidate certain acquired brands within the company’s healthcare portfolio.

“I want to thank all UPSers for their hard work and efforts,” said Carol Tomé, UPS chief executive officer. “Our financial performance in the first quarter was in line with our expectations, and average daily volume in the U.S. showed improvement through the quarter. Looking ahead, we expect to return to volume and revenue growth.”

U.S. Domestic Segment

1Q 2024 Adjusted1Q 2024 1Q 2023 Adjusted1Q 2023
Revenue $14,234 M $14,987 M
Operating profit $825 M $839 M $1,466 M $1,488 M
  • Revenue decreased 5.0%, driven by a 3.2% decrease in average daily volume.
  • Operating margin was 5.8%; adjusted operating margin was 5.9%.

International Segment

1Q 2024 Adjusted1Q 2024 1Q 2023 Adjusted1Q 2023
Revenue $4,256 M $4,543 M
Operating profit $656 M $682 M $828 M $806 M
  • Revenue decreased 6.3%, driven by a 5.8% decrease in average daily volume.
  • Operating margin was 15.4%; adjusted operating margin was 16.0%.

Supply Chain Solutions1

1Q 2024 Adjusted1Q 2024 1Q 2023 Adjusted1Q 2023
Revenue $3,216 M $3,395 M
Operating profit $132 M $226 M $247 M $258 M

1 Consists of operating segments that do not meet the criteria of a reportable segment under ASC Topic 280 – Segment Reporting.

  • Revenue decreased 5.3% primarily due to market rate declines in forwarding.
  • Operating margin was 4.1%; adjusted operating margin was 7.0%.

2024 Outlook

The company provides certain guidance on an adjusted (non-GAAP) basis because it is not possible to predict or provide a reconciliation reflecting the impact of future pension adjustments or other unanticipated events, which would be included in reported (GAAP) results and could be material.

For 2024, UPS reaffirms its full-year, consolidated financial targets:

  • Consolidated revenue to range from approximately $92.0 billion to $94.5 billion
  • Consolidated adjusted operating margin to range from approximately 10.0% to 10.6%
  • Capital expenditures of approximately $4.5 billion

* “Adjusted” or “Adj.” amounts are non-GAAP financial measures. See the appendix to this release for a discussion of non-GAAP financial measures, including a reconciliation to the most closely correlated GAAP measure.

Contacts:

UPS Media Relations: 404-828-7123 or pr@ups.com

UPS Investor Relations: 404-828-6059 (option 4) or investor@ups.com

# # #

Conference Call Information

UPS CEO Carol Tomé and CFO Brian Newman will discuss first-quarter results with investors and analysts during a conference call at 8:30 a.m. ET, April 23, 2024. That call will be open to others through a live Webcast. To access the call, go to www.investors.ups.com and click on “Earnings Conference Call.” Additional financial information is included in the detailed financial schedules being posted on www.investors.ups.com under “Quarterly Earnings and Financials” and as furnished to the SEC as an exhibit to our Current Report on Form 8-K.

About UPS

UPS (NYSE: UPS) is one of the world’s largest companies, with 2023 revenue of $91.0 billion, and provides a broad range of integrated logistics solutions for customers in more than 200 countries and territories. Focused on its purpose statement, “Moving our world forward by delivering what matters,” the company’s approximately 500,000 employees embrace a strategy that is simply stated and powerfully executed: Customer First. People Led. Innovation Driven. UPS is committed to reducing its impact on the environment and supporting the communities we serve around the world. UPS also takes an unwavering stance in support of diversity, equity and inclusion. More information can be found at www.ups.com, www.about.ups.com and www.investors.ups.com.

Forward-Looking Statements

This release, our Annual Report on Form 10-K for the year ended December 31, 2023 and our other filings with the Securities and Exchange Commission contain and in the future may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than those of current or historical fact, and all statements accompanied by terms such as “will,” “believe,” “project,” “expect,” “estimate,” “assume,” “intend,” “anticipate,” “target,” “plan,” and similar terms, are intended to be forward-looking statements. Forward-looking statements are made subject to the safe harbor provisions of the federal securities laws pursuant to Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.

From time to time, we also include written or oral forward-looking statements in other publicly disclosed materials. Forward-looking statements may relate to our intent, belief, forecasts of, or current expectations about our strategic direction, prospects, future results, or future events; they do not relate strictly to historical or current facts. Management believes that these forward-looking statements are reasonable as and when made. However, caution should be taken not to place undue reliance on any forward-looking statements because such statements speak only as of the date when made and the future, by its very nature, cannot be predicted with certainty.

Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our historical experience and our present expectations or anticipated results. These risks and uncertainties include, but are not limited to: changes in general economic conditions in the U.S. or internationally; significant competition on a local, regional, national and international basis; changes in our relationships with our significant customers; our ability to attract and retain qualified employees; strikes, work stoppages or slowdowns by our employees; increased or more complex physical or operational security requirements; a significant cybersecurity incident, or increased data protection regulations; our ability to maintain our brand image and corporate reputation; impacts from global climate change; interruptions in or impacts on our business from natural or man-made events or disasters including terrorist attacks, epidemics or pandemics; exposure to changing economic, political, regulatory and social developments in international and emerging markets; our ability to realize the anticipated benefits from acquisitions, dispositions, joint ventures or strategic alliances; the effects of changing prices of energy, including gasoline, diesel, jet fuel, other fuels and interruptions in supplies of these commodities; changes in exchange rates or interest rates; our ability to accurately forecast our future capital investment needs; increases in our expenses or funding obligations relating to employee health, retiree health and/or pension benefits; our ability to manage insurance and claims expenses; changes in business strategy, government regulations or economic or market conditions that may result in impairments of our assets; potential additional U.S. or international tax liabilities; potential claims or litigation related to labor and employment, personal injury, property damage, business practices, environmental liability and other matters; and other risks discussed in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K for the year ended December 31, 2023, and subsequently filed reports. You should consider the limitations on, and risks associated with, forward-looking statements and not unduly rely on the accuracy of predictions contained in such forward-looking statements. We do not undertake any obligation to update forward-looking statements to reflect events, circumstances, changes in expectations, or the occurrence of unanticipated events after the date of those statements, except as required by law.

From time to time, we expect to participate in analyst and investor conferences. Materials provided or displayed at those conferences, such as slides and presentations, may be posted on our investor relations website at www.investors.ups.com under the heading ”Presentations” when made available. These presentations may contain new material nonpublic information about our company and you are encouraged to monitor this site for any new posts, as we may use this mechanism as a public announcement.

Reconciliation of GAAP and Non-GAAP Financial Measures

We supplement the reporting of our financial information determined under generally accepted accounting principles (”GAAP”) with certain non-GAAP financial measures.

Adjusted financial measures should be considered in addition to, and not as an alternative for, our reported results prepared in accordance with GAAP. Our adjusted financial measures do not represent a comprehensive basis of accounting and therefore may not be comparable to similarly titled measures reported by other companies.

Forward-Looking Non-GAAP Metrics

From time to time when presenting forward-looking non-GAAP metrics, we are unable to provide quantitative reconciliations to the most closely correlated GAAP measure due to the uncertainty in the timing, amount or nature of any adjustments, which could be material in any period.

Incentive Compensation Program Design Changes

During 2022, we completed certain structural changes to the design of our incentive compensation programs that resulted in a one-time, non-cash charge in connection with the accelerated vesting of certain equity incentive awards that we do not expect to repeat. We supplement the presentation of our operating profit, operating margin, income before income taxes, net income and earnings per share with non-GAAP measures that exclude the impact of these changes. We believe excluding the impacts of such changes allows users of our financial statements to more appropriately identify underlying growth trends in compensation and benefits expense.

Long-lived Asset Estimated Residual Value Changes

During the fourth quarter of 2022, we incurred a one-time, non-cash charge resulting from a reduction in the estimated residual value of our MD-11 fleet. We supplement the presentation of our operating profit, operating margin, income before income taxes, net income and earnings per share with non-GAAP measures that exclude the impact of this charge. We believe excluding the impact of this charge better enables users of our financial statements to understand the ongoing cost associated with our long-lived assets.

Transformation and Other Costs, and Asset Impairment Charges

We supplement the presentation of our operating profit, operating margin, income before income taxes, net income and earnings per share with non-GAAP measures that exclude the impact of charges related to transformation activities, asset impairments and other charges. We believe excluding the impact of these charges better enables users of our financial statements to view and evaluate underlying business performance from the perspective of management. We do not consider these costs when evaluating the operating performance of our business units, making decisions to allocate resources or in determining incentive compensation awards.

One-Time Compensation Payment

We supplement the presentation of our operating profit, operating margin, income before income taxes, net income and earnings per share with non-GAAP measures that exclude the impact of a one-time payment made to certain U.S.-based, non-union part-time supervisors following the ratification of our labor agreement with the Teamsters. We do not expect this or similar payments to recur. We believe excluding the impact of this one-time payment better enables users of our financial statements to view and evaluate underlying business performance from the same perspective as management.

Defined Benefit Pension and Postretirement Medical Plan Gains and Losses

We recognize changes in the fair value of plan assets and net actuarial gains and losses in excess of a 10% corridor (defined as 10% of the greater of the fair value of plan assets or the plan’s projected benefit obligation), as well as gains and losses resulting from plan curtailments and settlements, for our pension and postretirement defined benefit plans immediately as part of Investment income (expense) and other in the statements of consolidated income. We supplement the presentation of our income before income taxes, net income and earnings per share with adjusted measures that exclude the impact of these gains and losses and the related income tax effects. We believe excluding these defined benefit pension and postretirement plan gains and losses provides important supplemental information by removing the volatility associated with plan amendments and short-term changes in market interest rates, equity values and similar factors.

Free Cash Flow

We calculate free cash flow as cash flows from operating activities less capital expenditures, proceeds from disposals of property, plant and equipment, and plus or minus the net changes in other investing activities. We believe free cash flow is an important indicator of how much cash is generated by our ongoing business operations and we use this as a measure of incremental cash available to invest in our business, meet our debt obligations and return cash to shareowners.

Adjusted Return on Invested Capital

Adjusted ROIC is calculated as the trailing twelve months (“TTM”) of adjusted operating income divided by the average of total debt, non-current pension and postretirement benefit obligations and shareowners’ equity, at the current period end and the corresponding period end of the prior year. Because adjusted ROIC is not a measure defined by GAAP, we calculate it, in part, using non-GAAP financial measures that we believe are most indicative of our ongoing business performance. We consider adjusted ROIC to be a useful measure for evaluating the effectiveness and efficiency of our long-term capital investments.

Adjusted Total Debt / Adjusted EBITDA

Adjusted total debt is defined as our long-term debt and finance leases, including current maturities, plus non-current pension and postretirement benefit obligations. Adjusted EBITDA is defined as earnings before interest, taxes, depreciation and amortization adjusted for the impacts of incentive compensation program redesign, one-time compensation, goodwill & asset impairment charges, transformation and other costs, defined benefit plan gains and losses and other income. We believe the ratio of adjusted total debt to adjusted EBITDA is an important indicator of our financial strength, and is a ratio used by third parties when evaluating the level of our indebtedness.

Continue Reading

Trending

Copyright © 2017 Zox News Theme. Theme by MVP Themes, powered by WordPress.